Genolution

Genolution Debt/Market Cap

The Debt to Market Capitalization Ratio of Genolution (225220.KQ) as of Oct 22, 2026 is 73.62 %. In the previous year, Debt to Market Capitalization Ratio was 73.61 % — a change of 0.01% (higher).

Debt/Market Cap

73.62 %

YoY

0.01%

Last updated:

Debt to Market Capitalization Ratio of Genolution is 2024 73.62 % . Debt to Market Capitalization Ratio of Genolution was 2023 73.61 % . It decreases by 0.01% higher compared to the previous year.

The Genolution Debt/Market Cap history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/Market Cap
Date
Debt/Market Cap
Jan 1, 2017
0.00 KRW
Jan 1, 2018
5.02 KRW
Jan 1, 2019
10.86 KRW
Jan 1, 2020
20.33 KRW
Jan 1, 2021
0.00 KRW
Jan 1, 2022
46.05 KRW
Jan 1, 2023
73.61 KRW
Jan 1, 2024
73.62 KRW
The Genolution Debt/Market Cap history
YEARDebt/Market CapYoY
73.62 %+0.01%
73.61 %+59.85%
46.05 %—
0.00-100.00%
20.33 %+87.14%
10.86 %+116.19%
5.02 %—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Debt to Market Capitalization Ratio of Genolution is 73.62 % in 2024.

Debt to Market Capitalization Ratio of Genolution changed from 73.61 % to 73.62 %, representing a 0.01% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt to Market Capitalization Ratio Genolution since 2006 – with annual values, charts, and detailed analysis.

Debt/Market Cap compares total debt to the market value of equity. It provides a market-based view of financial leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt to Market Capitalization Ratio's Genolution with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Genolution

All Key Metrics — Genolution